[1] Lee BL, Bathija R and Weinreb RN. The definition of normal-tension glaucoma. J Glaucoma 1998; 7: 366-371.
[2] Weinreb RN, Aung T and Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014; 311: 1901-1911.
[3] Morad Y, Sharon E, Hefetz L and Nemet P. Corneal thickness and curvature in normal-tension glaucoma. Am J Ophthalmol 1998; 125: 164-168.
[4] Tanaka T, Narazaki M and Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
[5] Papanicolaou DA and Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 2000; 85: 1331-1333.
[6] Path G, Bornstein SR, Ehrhart-Bornstein M and Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82: 2343-2349.
[7] Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C and D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002; 3: 313-330.
[8] Yuan T, Ma H, Liu W, Niesen DB, Shah N, Crews R, Rose KN, Vattem DA and Seeram NP. Pomegranate's Neuroprotective Effects against Alzheimer's Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites. ACS Chem Neurosci 2016; 7: 26-33.
[9] Fisher J, Mizrahi T, Schori H, Yoles E, Levkovitch-Verbin H, Haggiag S, Revel M and Schwartz M. Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility. J Neuroimmunol 2001; 119: 1-9.
[10] Rivera-Chavez FA, Peters-Hybki DL, Barber RC and O'Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218-223.
[11] Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S and Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
[12] Chen X, Zeng K, Xu M, Hu X, Liu X, Xu T, He B, Pan Y, Sun H and Wang S. SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. Cell Death Dis 2018; 9: 982.
[13] Yu W, Ding J, He M, Chen Y, Wang R, Han Z, Xing EZ, Zhang C and Yeh S. Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene 2019; 38: 1225-1238.
[14] Zhang Q, Li X and Chen Z. LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR-484 in human lung cancer cells. J Cell Biochem 2018; 119: 4447-4457.
[15] Zhao H, Diao C, Wang X, Xie Y, Liu Y, Gao X, Han J and Li S. LncRNA BDNF-AS inhibits proliferation, migration, invasion and EMT in oesophageal cancer cells by targeting miR-214. J Cell Mol Med 2018;
[16] Wu J, Weng Y, He F, Liang D and Cai L. LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and development of non-small-cell lung cancer. Anticancer Drugs 2018; 29: 628-636.
[17] Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H and Muller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-8041.
[18] Gutschner T, Hammerle M and Diederichs S. MALAT1 -- a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 2013; 91: 791-801.
[19] Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigo R and Gingeras TR. Landscape of transcription in human cells. Nature 2012; 489: 101-108.
[20] Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR and Goel A. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis 2014; 35: 2731-2739.
[21] Kryger R, Fan L, Wilce PA and Jaquet V. MALAT-1, a non protein-coding RNA is upregulated in the cerebellum, hippocampus and brain stem of human alcoholics. Alcohol 2012; 46: 629-634.
[22] Nakazawa T, Shimura M, Tomita H, Akiyama H, Yoshioka Y, Kudou H and Tamai M. Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Curr Eye Res 2003; 26: 55-63.
[23] Dong Y, Liang G, Yuan B, Yang C, Gao R and Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol 2015; 36: 1477-1486.
[24] Zhao J, Li L and Peng L. MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway. Int J Clin Exp Pathol 2015; 8: 15947-15953.
[25] Zheng J, Feng X, Hou L, Cui Y, Zhu L, Ma J, Xia Z, Zhou W and Chen H. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol 2011; 31: 597-604.
[26] Li HB, You QS, Xu LX, Sun LX, Abdul Majid AS, Xia XB and Ji D. Long Non-Coding RNA-MALAT1 Mediates Retinal Ganglion Cell Apoptosis Through the PI3K/Akt Signaling Pathway in Rats with Glaucoma. Cell Physiol Biochem 2017; 43: 2117-2132.
[27] Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, Zhang Y, Xing Y and Xi T. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun 2016; 472: 262-269.
[28] Jin C, Yan B, Lu Q, Lin Y and Ma L. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumour Biol 2016; 37: 7383-7394.
[29] Wang G, Li Y, Peng Y, Tang J and Li H. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids Health Dis 2018; 17: 75.
[30] Wang CY, Liang CY, Feng SC, Lin KH, Lee HN, Shen YC, Wei LC, Chang CJ, Hsu MY, Yang YY and Chiu CH. Analysis of the Interleukin-6 (-174) Locus Polymorphism and Serum IL-6 Levels with the Severity of Normal Tension Glaucoma. Ophthalmic Res 2017; 57: 224-229.
[31] Chang J, Xu W, Du X and Hou J. MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS. Onco Targets Ther 2018; 11: 3461-3473.
[32] Kholghi Oskooei V, Geranpayeh L, Omrani MD and Ghafouri-Fard S. Assessment of functional variants and expression of long noncoding RNAs in vitamin D receptor signaling in breast cancer. Cancer Manag Res 2018; 10: 3451-3462.
[33] Zhao G, Su Z, Song D, Mao Y and Mao X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-kappaB. FEBS Lett 2016; 590: 2884-2895.
[34] Cervantes-Gracia K and Husi H. Integrative analysis of Multiple Sclerosis using a systems biology approach. Sci Rep 2018; 8: 5633.
[35] Shi TY, Zhu ML, He J, Wang MY, Li QX, Zhou XY, Sun MH, Shao ZM, Yu KD, Cheng X, Wu X and Wei Q. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet 2013; 132: 301-312.
[36] Yang W, Hong L, Xu X, Wang Q, Huang J and Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol 2017; 39: 1010428317711315.
[37] Weiss M, Brandenburg LO, Burchardt M and Stope MB. MicroRNA-1 properties in cancer regulatory networks and tumor biology. Crit Rev Oncol Hematol 2016; 104: 71-77.
[38] Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and Seki N. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2012; 106: 405-413.
[39] Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM and Ambs S. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40: 3689-3703.
[40] Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P and Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013; 32: 296-306.
[41] Liu R, Li J, Lai Y, Liao Y and Qiu W. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. Int J Biol Macromol 2015; 81: 491-497.
[42] Kishimoto T, Akira S, Narazaki M and Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-1254.
[43] Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL and Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005; 174: 753-756.
[44] Huang P, Qi Y, Xu YS, Liu J, Liao D, Zhang SS and Zhang C. Serum cytokine alteration is associated with optic neuropathy in human primary open angle glaucoma. J Glaucoma 2010; 19: 324-330.
[45] Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, Cazzullo CL, Vergani C, Annoni G and Clerici M. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004; 25: 1009-1015.
[46] Lin KH, Feng SC, Shen YC, Wei LC, Liang CY, Chang CJ, Yang YY, Chiu CH and Wang CY. Interleukin-6(-174) locus polymorphism and serum IL-6 levels in normal tension glaucoma. Ophthalmic Genet 2014; 35: 255-257.
[47] Gani DK, Lakshmi D, Krishnan R and Emmadi P. Evaluation of C-reactive protein and interleukin-6 in the peripheral blood of patients with chronic periodontitis. J Indian Soc Periodontol 2009; 13: 69-74.